UNSPSC 51184009: Glipizide

This classification denotes an anti-diabetic agent with the molecular formula C21H27N5O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) X7WDT95N5C, chemically known as urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)- but more generally known as glipizide, which bears US NIH Compound Identifier 3478. European Medicines Agency schedules Glipizide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07927MIG.

UNSPSC 51184009 Glipizide is a Commodity code for a specific diabetes medication, though state and local procurement under this code appears driven by broader generic pharmaceutical sourcing initiatives rather than glipizide purchases in isolation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, recently issued an RFP to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. This procurement illustrates how state and local bodies use UNSPSC commodity codes to tag opportunities within larger therapeutic or product-class frameworks rather than to procure individual drugs by name. Vendors responding to MMCAP's RFP must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and comply with cGMP certification, DSCSA compliance, FDA requirements, and specific insurance thresholds including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability. Pricing is weighted most heavily at 75 percent of the evaluation, with the remaining 25 percent distributed across fixed pricing structure (10 percent), administrative fee compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent).

MMCAP is a repeat buyer under this code, drawing participation from state health agencies and local government healthcare facilities across the upper Midwest and Pacific Northwest. The RFP response deadline is March 26, 2026, with questions closed as of February 18, 2026; awarded contracts become effective July 1, 2026, for an initial two-year term with optional MMCAP extensions. The procurement does not identify set-aside preferences or business-classification restrictions, and MMCAP reserves sole, dual, or multi-award authority based on therapeutic considerations, product availability, and member-specific needs. Performance penalties ranging from $200 to $1,500 per violation apply for late reporting, missed onboarding timelines, or improper class-of-trade denials. Specific award values or budget ranges are not disclosed.